Last Updated: September 27, 2026

Details for Patent: 11,261,447

Name: Drug Patent Intelligence for US Patent 11261447
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,261,447 protect, and when does it expire?

Patent 11,261,447 protects OXLUMO and is included in one NDA.

This patent has ten patent family members in five countries.

Summary for Patent: 11,261,447

Title:	Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Abstract:	The invention relates methods of using RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.
Inventor(s):	David V. Erbe, Tracy L. McGregor
Assignee:	Alnylam Pharmaceuticals Inc
Application Number:	US16/630,800
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 11,261,447

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alnylam Pharms Inc	OXLUMO	lumasiran sodium	SOLUTION;SUBCUTANEOUS	214103-001	Nov 23, 2020		RX	Yes	Yes	11,261,447	⤷ Start Trial	Y	Y		TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 11,261,447

PCT Information
PCT Filed	July 12, 2018	PCT Application Number:	PCT/US2018/041891
PCT Publication Date:	January 17, 2019	PCT Publication Number:	WO2019/014491

International Family Members for US Patent 11,261,447

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018301829	⤷ Start Trial
Australia	2024227498	⤷ Start Trial
Canada	3069451	⤷ Start Trial
European Patent Office	3651775	⤷ Start Trial
Japan	2020526553	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.